Download video

Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)

289 views

VJOncology

2 years ago

Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)

Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)

Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)
2:25
Subgroups of metastatic hormone-sensitive prostate cancer (mHSPC)
by VJOncology
mHSPC prognostic subgroups
2:05
mHSPC prognostic subgroups
by VJOncology
PCa Commentary: METASTATIC HORMONE SENSITIVE PROSTATE CANCER (mHSPC): Many Treatment Options
13:09
PCa Commentary: METASTATIC HORMONE SENSITIVE PROSTATE CANCER (mHSPC): Many Treatment Options
by Grand Rounds in Urology
ARCHES: enzalutamide plus ADT in mHSPC subgroups
2:18
ARCHES: enzalutamide plus ADT in mHSPC subgroups
by VJOncology
ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancer
1:56
ARASENS: dialuramide plus ADT and docetaxel for metastatic hormone-sensitive prostate cancer
by VJOncology
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
3:51
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
by Bayer Global
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
16:26
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
by Grand Rounds in Urology
Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial
5:11
Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial
by Grand Rounds in Urology
Metastatic hormone sensitive prostate cancer
1:06:24
Metastatic hormone sensitive prostate cancer
by European School of Urology
Understanding Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Dr. Fred Saad
4:52
Understanding Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Dr. Fred Saad
by Bayer Global
Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer
2:27
Triplet Therapy for Metastatic Hormone-sensitive Prostate Cancer
by ASCOcancer
ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC
1:35
ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPC
by VJOncology
Current standards for first-line metastatic hormone-sensitive prostate cancer
2:10
Current standards for first-line metastatic hormone-sensitive prostate cancer
by VJOncology
Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists
1:01:45
Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists
by AUAUniversity
The evolving treatment landscape of mHSPC and mCRPC
1:23
The evolving treatment landscape of mHSPC and mCRPC
by VJOncology
ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC
1:44
ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC
by VJOncology
Axel Merseburger, ESMO 2019 - Advances in metastatic hormone-sensitive prostate cancer
4:40
Axel Merseburger, ESMO 2019 - Advances in metastatic hormone-sensitive prostate cancer
by Touch Medical Media
The evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
3:44
The evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
by VJOncology
Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer
1:07
Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer
by OncLive
Advanced \& metastatic prostate cancer at ASCO GU
4:51
Advanced \& metastatic prostate cancer at ASCO GU
by VJOncology